EVC
IMMX icon

Eidelman Virant Capital’s Immix Biopharma IMMX Stock Holding History

Eidelman Virant Capital’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-29,856
Closed -$103K – 203
2021
Q4 		$103K Buy
+29,856
New +$102K 0.04% 202

Other funds holding IMMX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ICG
InterOcean Capital Group Nashville, Tennessee $4.19B AUM 26.29% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Eidelman Virant Capital's IMMX Position: Q1 2022 in Review

Eidelman Virant Capital sold out of Immix Biopharma (IMMX) in Q1 2022, closing a stake of 29,856 shares — an estimated $103K sold.

Eidelman Virant Capital first reported a position in IMMX in Q4 2021 and held it in 1 quarter. The position peaked at $103K in Q4 2021. 8 funds tracked by Wall St. Rank hold IMMX as of Q1 2022.

  • Eidelman Virant Capital reported no remaining Immix Biopharma position as of Q1 2022 after selling out during the quarter.
  • Eidelman Virant Capital sold 29,856 Immix Biopharma shares in Q1 2022, an estimated $103K.
  • Eidelman Virant Capital first reported a position in Immix Biopharma in Q4 2021 and held it in 1 quarter.
  • Eidelman Virant Capital's Immix Biopharma position peaked at $103K in Q4 2021.
  • 8 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2022.

Based on Eidelman Virant Capital's 13F filing for Q1 2022, filed 12 Apr 2022.